Today's News

Richmond, BC, August 10, 2017--(T-Net)--Zecotek Photonics Inc. (TSX VENTURE: ZMS), a developer of leading-edge photonics technologies for healthcare, industrial and scientific markets, today announced that the Company has increased the non-brokered private placement financing, announced on July 18, 2017, to $2,455,005.

As previously announced on July 26, 2017, the Company closed the first tranche of the private placement by selling 3,995,000 units of the Company at a price of $0.30 per unit for gross proceeds of $1,198,500.

Net proceeds from the funds raised will be used to complete the transfer of technology for the purpose of immediate commercialization, strengthen and maintain patents of the Company's IP portfolio, and used for purchase order financings and general working capital purposes.

The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances, the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), the University of Washington (United States), and National NanoFab Center (South Korea). For more information visit www.zecotek.com and follow @zecotek on Twitter.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.